Compounds possessingneurotrophic properties may represent a possible treatment for neurodegenerative disorders such as amyotrophic lateral sclerosis. Xaliproden (SR57746A), an orally-active non-peptide compound, which has been found to exhibit neurotrophic effects in vitro and in vivo, increase the lifespan and delay the progression of motor neuron degeneration in PMN mice. We have used a quantitative reverse transcription/polymerase chain reaction amplification technique to study the regulation of neurotrophin mRNA and trk mRNA expression in PMN mice. NGF and NT-3 mRNA are downregulated in PMN mice. These deficiencies can be overcome by treatment with xaliproden. Such an effect could contribute to neurotrophic effects of xaliproden in vivo and in vitro.
Previous works have shown that many neurotrophic factors have an important effect in alleviating the severity of symptoms, in animal models, of motoneuron disease (I). Members of the neurotrophin family, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT-3), bind to a lowaffinity NGF cell surface receptor known as p75NGFR (2) ; however the role of p75NGFR in signal transduction remains unclear and is currently under intense investigation (3) (4) (5) (6) (7) . Neurotrophins also interact with tyrosine kinase receptors (Trk) which mediate neurotrophin signaling through tyrosine autophosphorylations (8-t 7) . So far, the preferred ligands oftrkA, trkB and trkC, are NGF, BDNF and NT -3, respectively (18) .
Natural growth factors are often toxic, have a very short half-life and do not easily cross the blood-brain barrier so that their therapeutic use is very limited. Some synthetic non peptide neurotrophic compounds have been developed to overcome these difficulties. Xaliproden (SR57746A) {1-(2-(naphtyl-2-yl)ethyl)-4-(3trifluoromethylphenyl) 1,2,5,6-tetrahydropyridine hydrochloride} is one ofthese molecules. It displays a wide range of neurotrophic effects in vivo as well as in vitro (19) . In vivo (20) , it increases the mean survival-time and motor performances of PMN mice (progressive motor neuronopathy), a model of inherited axonopathy (2 t, 22) . In vitro, it promotes the phenotypic survival of mouse purified motoneurons (23) .
Here, we show that mRNA expression of two endogenous neurotrophic factors, NGF and NT-3, is impaired in PMN mouse. These deficiencies are overcome by xaliproden and this could contribute to neurotrophic effects of this compound in vivo and in vitro.
MATERIALS AND METHODS

Mice
Breeding pairs ofXT+/+PMN double heterozygous mice were provided by Dr. l-L. Guenet (Institut Pasteur, Paris, France) in 1994. From these pairs we developed a colony in our facilities by heterozygous brother-sister mating. Heterozygous mice have supernumerary toes, whereas homozygous +PMN/+PMN mice do not (24, 22) .
Drug administration
Xaliproden (batch 94-0 I) was synthesized in the laboratories ofSanofi Recherche (Montpellier, France). The drug was suspended in an aqueous solution of 0,6% methylcellulose (metolose, Seppic, Paris, France; a generous gift of Dr. G. Le Calvez). In order to treat the animals immediately at birth, it was decided to administer the compound by treating the mothers, so that the offspring would receive the compound via the maternal milk. It has been shown that the compound was excreted into the maternal milk for approximately 0,0 I% (Fournier et al., personal communication) (20) . Based on past data, the treatment schedule selected was 5 mg kg", per os, administered every two days to the mothers. At this concentration, Xaliproden delayed the apparition of spontaneous denervation activity in the gastrocnemious and diaphragm muscles. Furthermore, the survival of the mice was significantly prolonged (19) (20) . Xaliproden or its vehicle was administered to groups of six PMN mice.
Reverse transcriptase-polymerase chain reaction (RT-peR)
RNA were extracted from spinal cord and brain using Trireagent" (Euromedex, Souffleweyersheim, France). Reverse transcription (RT) was carried out for 45 min at 42°C using 500 units of reverse transcriptase (Life Technologies, Cergy-Pontoise, France) in RT buffer (50 mM de Tris-HCI, 75 mmol/I de HCI), 10 mmol/I dithiothreitol, 3 mmol/I MgCI 2 , I mg RNA, 10 units human placental RNAse inhibitor (Life Technologies), 10 nmolll dNTP, 10 mmol/l random primer hexamer (Life Technologies).
PCR was performed using 1,25 U Taq polymerase (Life Technologies) and 25 pmol/l of primers (Genosys, Pampisford, England). The amplification was done in a Perkin-Elmer thermocycler geneAmp PCR system 9700 (Boston, MA, USA) according to the following scheme: (a) denaturation at 92°C for 3 min; (b) 35 amplification cycles (denaturation: I min at 92°C; hybridization: I min at hybridization temperature of the primers; elongation: I min at n°C) ; (c) final elongation for 7 min at noc.
Length and purity of reaction products were analysed by agarose (Euromedex) gel electrophoresis in presence of ethidium bromide (Gibco). Bands were analyzed and quantified with Optilab software (Graftec, France).
The primers were designed using oligos 4.05 sofware (National biosciences Inc., Plymouth, MA, USA).
The primers used for reverse transcription and polymerase chain reaction were (a) for NGF mRNAs : 5' -GTTTTGGCCTGTGTTCGTTGCAG-3' (sense primer) and 5'-CGCTTGCTCCGGTGAGTCCT-3' (antisense primer); (b) for BDNF mRNAs: 5'-ATGACCATCCTTTTCCTTACTATGGTT-3' (sense primer) and 5'-CCACTATCTTCCCI I I I IAATGGTC-3' (antisense primer); (c) for NT-3 mRNAs: 5'-GAAAATTACCAGAGCACCC-3' (sense primer) and 5' -TGACTCTTATGTTCTGCATAGC-3' (antisense primer) ; (d) for trkA mRNAs : 5' -CGTCATGGCTGCT TTTATG-3' (sense primer) and 5' -ACTGGCGAGAAG GAGACAG-3' (antisense primer) ; (e) fortrkB mRNAs : 5' -AATGAAACAAGCCACACACAG-3' (sense primer) and 5'-TGATATGGCCCCATTGTAGA-3' (antisense primer) ; (f) for trkC mRNAs: 5'-TGGACATGGAGCTCTACACG-3' (sense primer) and 5'-GCACTGATGCAGTAAAGGCTC-3' (antisense primer) ; (g) for GAPDH (glyceraldehyde phosphate deshydrogenase) mRNAs : 5' -CACCATCTTCCAGGA GCGAG-3' (sense primer) and 5'-GTTCAGCTCTGG GATGACCTT-3' (antisense primer) ; GAPDH gene is a housekeeping gene, currently used as reference gene for quantification of mRNA expression.
Statistical analysis
Results are given as mean ± standard error of the mean (sem). Differences between drug-treated and vehicle-treated mice were compared using one way ANOVA test, followed by Fisher test for multiple comparisons.
RESULTS
Semi-quantification of neurotrophin and neurotrophin receptors mRNA in healthy and affected PMN mice.
mRNA quantification in brain and spinal cord was determined by RT-PCR and the amount of mRNA was reported to the amount of GAPDH mRNA. The results are presented in Fig. I and 2 . No statistical significant difference was observed either in brain or in spinal cord at all time points studied for the following factors: BDNF and trkC. NT-3 mRNA could not be detected in the spinal cord. However, NGF and NT-3 mRNA decreased precociously in affected mice in spinal cord and in brain respectively (P<0,05). We also observed in affected PMN mice an increase of the expression oftrkA and trkB receptors mRNA at 16 days (trkA Fig. 1 . Expression ofneurotrophins in affected and healthy PMN mice. RNA were extractedfrom spinal cord and brain as described in Materials and Methods. and subjected to a RT-PCR. The quantity ofinterest mRNA is correlated by the quantity ofGAPDH mRNA which is a housekeeping gene. The results were representative of six mice. Results are given as mean ± s.e.mean. Differences between affected and healthy mice were compared using one way ANOVA test,followed by Fisher testfor multiple comparisons. and trkB) and at 24 days (trkA) postnatal (P< 0,05). These up-regulations could be explained by a compensatory mechanism: the deficit in NGF and NT-3 mRNA expression in affected mice would result in an increased expression of their receptors.
In order to determine if xaliproden could increase the expression of neurotrophins and their associated receptors in vivo, we have performed a semi-quantitative study in spinal cord and brain of PMN mouse treated by xaliproden at the concentration where it has an optimal effect.
Xaliproden effect on neurotrophin and neurotrophin receptors mRNA expression in PMN mice
No modification in mRNA expression of neurotrophin receptors was observed in treated mice (data not shown). Xaliproden did not exert any effect on mRNA expression of BDNF, either in brain or in spinal cord (Fig. 3) . After 16 days of treatment, we observed an increase in NGF mRNA expression in spinal cord as well as in brain of affected animals. Xaliproden also increased NT-3 mRNA expression only in brain of 16 days old affected mice.
Fig. 2. Expression ofneurotrophins receptors in affected and healthy PMN mice.
RNA were extractedfrom spinal cord and brain as described in Materials and Methods and subjected to a RT-PCR. The quantity of interest mRNA is correlated by the quantity of GAPDH mRNA which is a housekeeping gene. The results were representative of six mice. Results are given as mean ± s.e.mean. Differences between affected and healthy mice were compared using one way ANOVA test,followed by Fisher testfor multiple comparisons.
DISCUSSION
In this study, we showed that NT-3 and NGF mRNA are down-regulated in PMN mice and that xaliproden increased the expression of the mRNA of these two neurotrophins in affected mice. This result could explain the neuroprotective effect of xaliproden in PMN mice.
The mouse mutant PMN is an autosomal, recessively inherited mutation which causes a progressive dying back axonal degeneration, Fig. 3 . Effect ofXALIPRODEN on mRNA expression of neurotrophins and their associated receptors in affected and healthy PMN mice. RNA were extracted from spinal cord and brain -as described in Materials and Methods and subjected to a RT-PCR. The quantity of interest mRNA is correlated by the quantity ofGAPDHmRNA which is a housekeeping gene. The results were representative of six mice. Results are given as mean :J: s.e.mean. Differences between treated and untreated mice were compared using one way ANOVA test, followed by Fisher test for multiple comparisons.
principally of the larger-diameter myelinated motor axons. Our data indicate that affected PMN mouse displays an early deficit in NGF and NT-3 mRNA expression. Moreover, affected mice treated with Xaliproden had a lifespan 50 % longer than that of untreated mice. Compared to untreated PMN mice, this compound improved the performance of the PMN mice in three behavioural tasks (20) .
In many experimental models, xaliproden elicits activities similar to those of neurotrophic factors, particularly NGF (25) . The neurotrophic factor promoting activity of xaliproden was evaluated in primary cultures of rat astrocytes by studying the synthesis of various neurotrophins. As assessed by quantitative analysis, a concentration-dependent and time-dependent increase of NGF mRNA was induced by xaliproden in cortical astrocytes, whereas BDNF mRNA content was increased to a significant but smaller extent. These results suggest that xaliproden enhances the synthesis of neurotrophins in astrocytes (26) .
Our results strongly suggest that xaliproden might exert neuroprotective effects partly via stimulation ofNT-3 and NGF synthesis. Although NGF has little effect on survival of motoneurons (27), NT-3 is well known to promote it. However, NGF is now known to be essential to preserve the cholinergic neurons of the basal nucleus ofMeynert in culture, in relation to Alzheimer's disease (28) . Previously, Haase et at. (29) demonstrated that adenovirus-mediated gene transfer of NT-3 could produce substantial therapeutic effects in the mouse mutant PMN. After intramuscular injection of NT-3 adenoviral vector, PMN mice showed a 50 % increase in life span, reduced loss of motor axons and improved neuromuscular function as assessed by electromyography. In addition, NT-3 is largely known to be involved in the survival of motoneurons in vivo (30, 31) and in vitro (32) . The down-regulation of NGF seems to be the consequence of PMN disease since no link is known between NGF and the survival of motoneurons. Moreover, the decrease of NGF biosynthesis by root ganglia cells could result from motoneuronal death.
Recently, the PMN mutation has been identified as resulting in a Trp524Gly substitution at the last residue of the tubulin-specific chaperone protein that leads to decreased protein stability. This instability results in a reduced number of microtubules in sciatic and phrenic nerves of affected mice (33) . Moreover, in PC 12cells, NGF stimulated expression of the growth-associated protein GAP431 B-50 and tubulin and this up-regulation was associated with enhanced neurite outgrowth (34) . Xaliproden, by stimulating NGF synthesis, could prevent the instability of microtubules induced by PMN mutation.
In conclusion, our data suggest that xaliproden increased the expression of two neurotrophins mRNA which have a major function in protecting the nervous system. Nevertheless, these results regarding the mRNA expression are confirmed by the study of the protein expression of neurotrophins and their associated receptors.
